Willerson J T, Yao S K, McNatt J, Benedict C R, Anderson H V, Golino P, Murphree S S, Buja L M
Department of Internal Medicine, University of Texas Medical School, Houston 77030.
Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10624-8. doi: 10.1073/pnas.88.23.10624.
The role of recurrent platelet aggregation in the development of neointimal proliferation of coronary arteries was explored in this study, and the hypothesis was evaluated that recurrent platelet aggregation and the consequent frequency and severity of cyclic coronary blood flow variations are important pathophysiologic factors in the subsequent development of neointimal proliferation. In 24 chronically instrumented dogs, variable degrees of coronary artery neointimal proliferation were observed 3 weeks after mechanical injury of the arterial endothelium and the placement of an external coronary artery constrictor. The severity of neointimal proliferation at 21 days was closely related to the frequency and severity of cyclic coronary blood flow variations during the initial 7 days after instrumentation of the animals, itself a manifestation of recurrent platelet aggregation and dislodgement. Pharmacological therapy with a dual thromboxane A2 synthetase inhibitor and receptor antagonist and with a serotonin S2 receptor antagonist frequently was successful in abolishing cyclic blood flow variations and in retarding neointimal proliferation.
本研究探讨了复发性血小板聚集在冠状动脉内膜增生发展中的作用,并对以下假说进行了评估:复发性血小板聚集以及随之而来的冠状动脉血流周期性变化的频率和严重程度是内膜增生后续发展的重要病理生理因素。在24只长期植入仪器的犬中,在动脉内皮机械损伤并放置冠状动脉外缩窄器3周后,观察到不同程度的冠状动脉内膜增生。术后21天内膜增生的严重程度与动物植入仪器后最初7天冠状动脉血流周期性变化的频率和严重程度密切相关,而这种变化本身就是复发性血小板聚集和脱落的表现。使用双血栓素A2合成酶抑制剂和受体拮抗剂以及血清素S2受体拮抗剂进行药物治疗,常常能成功消除血流周期性变化并延缓内膜增生。